Mark KelleyMelissa FishelMark Kelley and Melissa Fishel, two researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, received a five-year, $2.4 million grant from NCI to explore therapies that target the critical pathways pancreatic tumors use to survive.
IU Health and the Indiana University Melvin and Bren Simon Comprehensive Cancer Center plans to develop a state-wide mobile lung cancer screening program as a result of a $4.5 million gift from The Tom and Julie Wood Family Foundation, which includes $4 million matching dollars from Indiana University Health.
Three patients in Mozambique have started treatment for HER2- HR+ advanced breast cancer, including CDK4/6 inhibitor therapy through The Max Foundation’s Max Access Solutions program.
Preliminary data from Arm A1 of the phase II EDGE-Gastric study showed promising overall response rate and six-month progression-free-survival results, irrespective of PD-L1 expression.
Positive high-level results from the EMERALD-1 phase III trial showed Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival versus TACE alone in patients with hepatocellular carcinoma eligible for embolization. The trial continues to follow the secondary endpoint of overall survival.
A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment can impact treatment responses and outcomes in patients newly diagnosed with multiple myeloma who undergo combination treatments that include targeted immunotherapy.
UCLA scientists developed a novel method to engineer more powerful immune cells that can potentially be used for “off-the-shelf” cell therapy to treat challenging cancers.
An international collaboration led by USC compiled the most comprehensive list of genetic variants associated with prostate cancer risk through a whole-genome analysis that ranks as the largest and most diverse investigation into prostate cancer genetics yet.
FDA approved Fruzaqla (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
FDA revised the existing indication of Keytruda (pembrolizumab) with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
